Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis

Naba R. Mainali; Vijaya R. Bhatt; Shiksha Kedia; Jairam Krishnamurthy; Laura M. Wake; Mojtaba Akhtari

doi:10.1177/1078155213504444

Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis

Naba R. Mainali, Vijaya R. Bhatt, Shiksha Kedia, Jairam Krishnamurthy, Laura M. Wake, Mojtaba Akhtari

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.

Original language	English (US)
Pages (from-to)	386-392
Number of pages	7
Journal	Journal of Oncology Pharmacy Practice
Volume	20
Issue number	5
DOIs	https://doi.org/10.1177/1078155213504444
State	Published - Oct 1 2014
Externally published	Yes

Keywords

Bone marrow aplasia
immunosuppression
myelosuppression
pancytopenia
pegylated interferon-α-2a
primary myelofibrosis

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1177/1078155213504444

Cite this

@article{d47cc940a4cf4695b83e8b8887fabed3,

title = "Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis",

abstract = "Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.",

keywords = "Bone marrow aplasia, immunosuppression, myelosuppression, pancytopenia, pegylated interferon-α-2a, primary myelofibrosis",

author = "Mainali, {Naba R.} and Bhatt, {Vijaya R.} and Shiksha Kedia and Jairam Krishnamurthy and Wake, {Laura M.} and Mojtaba Akhtari",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2013.",

year = "2014",

month = oct,

day = "1",

doi = "10.1177/1078155213504444",

language = "English (US)",

volume = "20",

pages = "386--392",

journal = "Journal of Oncology Pharmacy Practice",

issn = "1078-1552",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis

AU - Mainali, Naba R.

AU - Bhatt, Vijaya R.

AU - Kedia, Shiksha

AU - Krishnamurthy, Jairam

AU - Wake, Laura M.

AU - Akhtari, Mojtaba

N1 - Publisher Copyright: © The Author(s) 2013.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.

AB - Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.

KW - Bone marrow aplasia

KW - immunosuppression

KW - myelosuppression

KW - pancytopenia

KW - pegylated interferon-α-2a

KW - primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84907218787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907218787&partnerID=8YFLogxK

U2 - 10.1177/1078155213504444

DO - 10.1177/1078155213504444

M3 - Article

C2 - 24067929

AN - SCOPUS:84907218787

SN - 1078-1552

VL - 20

SP - 386

EP - 392

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

IS - 5

ER -

Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this